Latest Conference Articles

March 10th 2020, 8:12pm

PER® Miami Breast Cancer Conference

What may have worked before to mitigate burnout may no longer work now because we change, and so do our work environments.

March 10th 2020, 5:40pm

PER® Miami Breast Cancer Conference

Genetic advances have helped elucidate the heterogenous nature of breast cancer, however optimal strategies for patients with early-stage disease still need to be ironed out.

March 10th 2020, 12:13am

PER® Miami Breast Cancer Conference

The inclusion of patients from the time of diagnosis and encompassing family, friends, and caregivers is central to moving survivorship care forward, especially for breast cancer survivorship, which has high survival rates for early disease and the emergence of novel treatments for advanced cancers.

March 9th 2020, 12:01am

PER® Miami Breast Cancer Conference

Joyce A. O'Shaughnessy, MD, discusses the utility of targeting capivasertib in targeting Akt mutations in breast cancer.

March 8th 2020, 11:50pm

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, discusses personalized therapy options in metastatic breast cancer.

March 8th 2020, 7:26pm

PER® Miami Breast Cancer Conference

The novel coronavirus spreading across the world represents a distinct challenge for all physicians, especially oncologists who commonly treat patients who have compromised immune systems.

March 8th 2020, 7:12pm

PER® Miami Breast Cancer Conference

Special attention to reducing the risk of cardiovascular disease should be a priority for long-term care of patients with breast cancer.

March 8th 2020, 5:12am

PER® Miami Breast Cancer Conference

Patrick I. Borgen, MD, discusses the trend toward surgical de-escalation in patients with breast cancer.

March 8th 2020, 4:33am

PER® Miami Breast Cancer Conference

Enrique Soto Pérez de Celis, MD, MSc, discusses nuances of treating older patients with breast cancer.

March 7th 2020, 11:39pm

PER® Miami Breast Cancer Conference

Novel antibody-drug conjugates have demonstrated high response rates in patients with heavily pretreated metastatic breast cancer, and ongoing studies targeting actionable cell-surface markers may further expand their clinical utility, according to Aditya Bardia, MD, MPH.

March 7th 2020, 9:17pm

PER® Miami Breast Cancer Conference

Hope S. Rugo, MD, discusses the pending approval of tucatinib in metastatic HER2-positive breast cancer and other potentially practice-changing agents in the pipeline.

March 7th 2020, 7:54pm

PER® Miami Breast Cancer Conference

Physicians should “get out there and test early and often,” to align with a potential new paradigm for genetic testing that allows anyone on the treatment team to identify and test individuals, with the specialist ultimately providing risk management, according to Kevin S. Hughes, MD, FACS.

March 7th 2020, 2:39am

PER® Miami Breast Cancer Conference

Breast cancer has historically been an immunologically cold disease, but recent and emerging data are carving out a space for several immunotherapies in the treatment paradigm.

March 7th 2020, 12:52am

PER® Miami Breast Cancer Conference

Kevin Hughes, MD, discusses the role of genetic testing in breast cancer.

March 7th 2020, 12:01am

PER® Miami Breast Cancer Conference

Gene profiling assays can accurately and reproducibly assist decision making for patients with hormone receptor-positive breast cancer, with the ultimate goal of improving outcomes or avoiding toxicity.

March 6th 2020, 11:51pm

PER® Miami Breast Cancer Conference

Mark E. Robson, MD, discusses the potential utility of tucatinib in the treatment of patients with HER2-positive breast cancer.

March 6th 2020, 9:12pm

PER® Miami Breast Cancer Conference

The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings.

March 6th 2020, 2:45am

PER® Miami Breast Cancer Conference

Given the solid correlation between the risk of locoregional recurrence (LRR) and distant recurrence, several investigators have examined whether genomic assays that predict risk of distant recurrence can also predict risk of LRR.

March 3rd 2020, 3:59am

HCC-TAG Conference

There are clear biomarkers available to guide treatment decisions in the second-line setting for patients with advanced hepatocellular carcinoma, Lipika Goyal, MD, Mphil, said during a presentation at the 2020 HCC-TAG Conference.

March 3rd 2020, 1:47am

HCC-TAG Conference

By 2025, Anthony El-Khoueiry, MD, expects to see a larger menu of approved drugs and drug combinations for the treatment of advanced hepatocellular carcinoma, better use of molecular and immune signatures to guide treatment decisions, and, possibly, the chance to cure intermediate- and advanced-stage disease.